Brauner R, Fontoura M, Zucker J M, Devergie A, Souberbielle J C, Prevot-Saucet C, Michon J, Gluckman E, Griscelli C, Fischer A
Hôpital et Faculté Necker Enfants Malades, Paris, France.
Arch Dis Child. 1993 Apr;68(4):458-63. doi: 10.1136/adc.68.4.458.
This study analyses the growth and the growth hormone secretion of children given various conditioning protocols before bone marrow transplantation (BMT). Twenty nine children (14 boys, 15 girls) given BMT were classified according to their conditioning protocol: total body irradiation (TBI) given as a single exposure of 10 Grays (Gy, group I, 11 cases), or 8 Gy (group II, four cases), 12 Gy given as six fractionated doses (Group III, seven cases), or chemotherapy alone (group IV, seven cases). The arginine-insulin stimulated growth hormone peak, 2-7.5 years after BMT, was > 10 micrograms/l in all patients except four from group I (6.9-8.9 micrograms/l). A second growth hormone secretion evaluation was performed in 10 group I patients because of persistent low growth velocity despite a normal growth hormone peak. There were no significant changes in the mean (SEM) stimulated growth hormone peak (18.4 (2.2) v 20.1 (3.6) micrograms/l) at 3 (0.3) to 5.2 (0.6) years after BMT. The sleep growth hormone peaks and concentrations (n = 6) were normal. The mean cumulative height changes (SD) during the three years after BMT were: -1.4 (0.2) in group I, -0.1 (0.4) in group II, -0.4 (0.2) in group III, and 1.5 (0.5) in group IV; this was significant in groups I and IV. The final heights of two monozygotic twins (BMT donor and recipient) had differed by 17.5 cm, despite them both having normal growth hormone peaks and puberty. Eight patients, treated for congenital immune deficiency syndrome, were growth retarded at the time of BMT. Of these, only those conditioned by chemotherapy alone had significant catch up growth (2(0.6)SD) while those conditioned by a single Gy exposure did not (0(0.4)SD). It is concluded that the total radiation dose is critical for growth evolution, as is the fractionation schedule. For the TBI doses and the interval since BMT studied, there was no correlation between growth hormone peak and the height loss. The rapidity of decreased growth velocity after TBI and the comparison between the monozygotic twins suggest that radiation induced skeletal lesions are partly responsible for the decreased growth.
本研究分析了接受骨髓移植(BMT)前采用不同预处理方案的儿童的生长情况及生长激素分泌情况。29例接受BMT的儿童(14例男孩,15例女孩)根据其预处理方案进行分类:全身照射(TBI),单次照射10格雷(Gy,I组,11例),或8 Gy(II组,4例),12 Gy分6次照射(III组,7例),或仅接受化疗(IV组,7例)。除I组4例患者(6.9 - 8.9微克/升)外,所有患者在BMT后2 - 7.5年精氨酸 - 胰岛素刺激的生长激素峰值均>10微克/升。由于尽管生长激素峰值正常但生长速度持续偏低,对10例I组患者进行了第二次生长激素分泌评估。BMT后3(0.3)至5.2(0.6)年时,刺激生长激素峰值的平均值(SEM)无显著变化(18.4(2.2)微克/升对20.1(3.6)微克/升)。睡眠时生长激素峰值及浓度(n = 6)正常。BMT后三年的平均累积身高变化(SD)为:I组-1.4(0.2),II组-0.1(0.4),III组-0.4(0.2),IV组1.5(0.5);I组和IV组差异有统计学意义。尽管一对同卵双胞胎(BMT供体和受体)的生长激素峰值和青春期均正常,但最终身高相差17.5厘米。8例先天性免疫缺陷综合征患者在BMT时生长发育迟缓。其中,仅接受化疗预处理的患者有显著的追赶生长(2(0.6)SD),而单次Gy照射预处理的患者则没有(0(0.4)SD)。结论是,总辐射剂量对生长演变至关重要,分次照射方案同样如此。对于所研究的TBI剂量及BMT后的时间间隔,生长激素峰值与身高损失之间无相关性。TBI后生长速度下降的速度以及同卵双胞胎之间的比较表明,辐射诱导的骨骼病变部分导致了生长减缓。